menu
    • menu
    [{"orgOrder":0,"company":"NeuroGenesis","sponsor":"Hadassah Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"NG-01","moa":"Stem cell proliferation","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroGenesis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"NeuroGenesis \/ Hadassah Medical Center","highestDevelopmentStatusID":"8","companyTruncated":"NeuroGenesis \/ Hadassah Medical Center"},{"orgOrder":0,"company":"NeuroGenesis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"NG-01","moa":"Stem cell proliferation","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroGenesis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"NeuroGenesis \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroGenesis \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by NeuroGenesis

    Menu

    NeuroGenesis

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            NeuroGenesis

                            U.S.A arrow
                            AMWC Asia-TDAC
                            Not Confirmed

                            NeuroGenesis

                            U.S.A arrow
                            AMWC Asia-TDAC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NG-01

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            NeuroGenesis Reports Positive Results from Phase 2 Study in Progressive Multiple Sclerosis

                            Details : NG-01 is a proprietary autologous bone marrow-derived stem cells designed to secrete high levels of remyelinating and neurotrophic factors at the CNS site of injury in multiple sclerosis.

                            Product Name : NG-01

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            December 03, 2024

                            Lead Product(s) : NG-01

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            NeuroGenesis

                            U.S.A arrow
                            AMWC Asia-TDAC
                            Not Confirmed

                            NeuroGenesis

                            U.S.A arrow
                            AMWC Asia-TDAC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NG-01

                            Therapeutic Area : Neurology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Hadassah Medical Center

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            NeuroGenesis and Hadassah Medical Center Report Positive NF-L Biomarker Results from a Phase 2 Study in Progre...

                            Details : Results published in Stem Cells Translational Medicine show significant reduction of NF-L, a biomarker for neuronal damage, in patients with progressive multiple sclerosis after treatment with NG-01 stem cells.

                            Product Name : NG-01

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            January 03, 2022

                            Lead Product(s) : NG-01

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Hadassah Medical Center

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth